Kenneth (Ken) Rosenfield, MD

Section Head, Vascular Medicine and Intervention

Chairman, STEMI & Acute MI Quality Improvement Committee

Kenneth Rosenfield, MD, is the Section Head for Vascular Medicine and Intervention and Chairs the Acute Myocardial Infarction(STEMI)Committee for the cardiac cath lab. He is a national leader in treatment of Carotid, Kidney, and Leg artery disease.

BiographyKenneth Rosenfield, MD, is the Section Head for Vascular Medicine and Intervention, who specializes in complex cardiac and vascular interventions and directs the program for treatment of acute myocardial infarction (STEMI) in the cardiac catheterization laboratories. He has spearheaded the development of less-invasive therapies for patients with coronary and vascular disease, both at MGH and nationally, including treatment of Carotid, Kidney, and Leg artery narrowing using stents and other novel devices.

Research

Dr. Rosenfield has served as national principle investigator (PI) for numerous clinical trials

Investigators from Massachusetts General Hospital revealed the results of the CREST trial, a study that looked at the efficacy of carotid endarterectomy versus stenting in patients with symptomatic carotid stenosis, and found that these two medical procedures are both equally safe and effective.

The medical community has made great strides treating coronary and carotid artery diseases and reducing mortality associated with myocardial infarctions and strokes. While as many as 3 million Americans have renal artery stenosis (RAS)—a condition that narrows or blocks the vessels that supply blood to the kidneys—RAS is often overlooked and underdiagnosed.

MGH Hotline 4.1.11 From the time a person first experiences symptoms of a heart attack, such as shortness of breath or chest discomfort, to the time he or she undergoes cardiac catheterization -- a procedure used to diagnose and treat a blocked coronary artery -- every second is of utmost importance.

A team of researchers from Brigham and Women's Hospital, Boston Medical Center and MGH has been awarded $25 million by the National Institutes of Health to conduct a clinical trial comparing traditional bypass surgery with a less invasive treatment alternative for patients with critical limb ischemia.